Open Label Dose Escalation Phase I Study to Investigate the Safety and Pharmacokinetics of T121E01F and T121E02F in Healthy Postmenopausal Women
PHASE1CompletedINTERVENTIONAL
Enrollment
71
Participants
Timeline
Start Date
January 31, 2013
Primary Completion Date
July 31, 2014
Study Completion Date
August 31, 2014
Conditions
Healthy Postmenopausal Women
Interventions
DRUG
T121
DRUG
Zoledronic acid
Trial Locations (1)
55114
Prism Clinical Research, Saint Paul
All Listed Sponsors
lead
Thar Pharmaceuticals, Inc
INDUSTRY
NCT01721993 - Open Label Dose Escalation Phase I Study to Investigate the Safety and Pharmacokinetics of T121E01F and T121E02F in Healthy Postmenopausal Women | Biotech Hunter | Biotech Hunter